MBRX Moleculin Biotech (MBRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001659617
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · no price filed
What the filings say about MBRX
Activist stakes (13D), 180 days
2 filings
Largest: 9.9% of the class
Moleculin Biotech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Moleculin Biotech, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 26, 2023.
- The trade is 94.0% of the 287,587 shares held after it.
- 1 other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Foster Jonathan P. bought about $100.0K of MBRX on Jun 23, 2025, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 26, 2023.
- +2.4% median (+1.0% mean) 90-day return after 5 previous buys.
- The trade is 90.9% of the 743,607 shares held after it.
- 1 other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President KLEMP WALTER V bought about $250.0K of MBRX on Jun 23, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
24.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
Foster Jonathan P. disclosed a 5%+ stake (6.3%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MBRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.2%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MBRX: institutional holders (13F)
13F holdings, latest reported quarter
47,252 sh
$131.8K
42,215 sh
$117.8K
29,883 sh
$83.4K
22,942 sh
$64.0K
20,036 sh
$55.9K
Congress trades in MBRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Foster Jonathan P.
Activist 13D · 2026-08-25
6.3%
KLEMP WALTER V
Activist 13D · 2026-08-25
9.9%
AnnaMed, Inc.
Activist 13D · 2026-08-25
0.1%
MBRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MBRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$61.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$78.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$12.5K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$8.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Walter V. Klemp
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$722.3K
$765.1K
-99%
n/a
2024
$1.5M
$339.6K
$841.9K
-89%
n/a
2023
$1.4M
$1.4M
$719.9K
-19%
n/a
2022
$2.0M
$1.5M
$895.9K
-78%
n/a
2021
$2.0M
$754.2K
$915.8K
-61%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MBRX financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MBRX
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$25.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MBRX
| FY Dec 2025 | -$22.7M |
| FY Dec 2024 | -$23.9M |
| FY Dec 2023 | -$23.7M |
| FY Dec 2022 | -$27.7M |
| FY Dec 2021 | -$19.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$5.4M |
| Sep 2025 | -$7.2M |
| Jun 2025 | -$5.6M |
| Mar 2025 | -$4.6M |
| Dec 2024 | -$5.1M |
| Sep 2024 | -$6.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+635.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MBRX
| FY Dec 2025 | +256.0% |
| FY Dec 2024 | +123.6% |
| FY Dec 2023 | +71.6% |
| FY Dec 2022 | -44.3% |
| FY Dec 2021 | -32.9% |
| Jun 2026 | +635.3% |
| Mar 2026 | +183.7% |
| Dec 2025 | +256.0% |
| Sep 2025 | n/a |
| Jun 2025 | +152.3% |
| Mar 2025 | +137.0% |
| Dec 2024 | +123.6% |
| Sep 2024 | +113.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+172.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MBRX
| FY Dec 2025 | +171.9% |
| FY Dec 2024 | +94.5% |
| FY Dec 2023 | +62.3% |
| FY Dec 2022 | -41.0% |
| FY Dec 2021 | -28.1% |
| Jun 2026 | +172.4% |
| Mar 2026 | +120.0% |
| Dec 2025 | +171.9% |
| Sep 2025 | -16.5% |
| Jun 2025 | +62.6% |
| Mar 2025 | +102.5% |
| Dec 2024 | +94.5% |
| Sep 2024 | +94.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-226.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MBRX
| FY Dec 2025 | -187.1% |
| FY Dec 2024 | -124.0% |
| FY Dec 2023 | -70.5% |
| FY Dec 2022 | -46.1% |
| FY Dec 2021 | -43.1% |
| Jun 2026 | -226.9% |
| Mar 2026 | -183.2% |
| Dec 2025 | -187.1% |
| Sep 2025 | -149.1% |
| Jun 2025 | -151.8% |
| Mar 2025 | -131.0% |
| Dec 2024 | -124.0% |
| Sep 2024 | -108.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-18.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield MBRX
| FY Dec 2025 | -13.5% |
| FY Dec 2024 | -18.7% |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | -0.2% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -170.3% |
| Mar 2026 | -198.7% |
| Dec 2025 | -13.5% |
| Sep 2025 | -5.6% |
| Jun 2025 | -20.0% |
| Mar 2025 | -6.4% |
| Dec 2024 | -18.7% |
| Sep 2024 | -13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing MBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M |
| Net income | $33.6M | $26.0M | $29.8M | -$29.0M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M |
| Cash | $8.9M | $4.3M | $23.6M | $43.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
MBRX Stock Sonar score 3/7 axes
Find similar shapesCompareMBRX ranks highest on profitability (69th percentile) and institutional and government (21st), and lowest on risk and compliance (8th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MBRX filings, in plain words
Read the full summary
2 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 9.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
